Follow
Ana M. Contreras-Sandoval
Ana M. Contreras-Sandoval
Unknown affiliation
No verified email
Title
Cited by
Cited by
Year
Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer
S Zalba, AM Contreras, A Haeri, TLM Ten Hagen, I Navarro, G Koning, ...
Journal of Controlled Release 210, 26-38, 2015
1222015
EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model
S Zalba, AM Contreras, M Merino, I Navarro, CT De Ilarduya, IF Trocóniz, ...
Nanomedicine 11 (5), 465-477, 2016
292016
A new immune-nanoplatform for promoting adaptive antitumor immune response
M Merino, A Contreras, N Casares, IF Troconiz, TL Ten Hagen, ...
Nanomedicine: Nanotechnology, Biology and Medicine 17, 13-25, 2019
252019
Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model
AM Contreras, M Merino, M Vasquez, IF Trocóniz, P Berraondo, ...
Oncotarget 7 (47), 76891, 2016
162016
Quantification of pharmacokinetic profiles of pd-1/pd-l1 antibodies by validated elisas
S Zalba, AM Contreras-Sandoval, E Martisova, R Debets, C Smerdou, ...
Pharmaceutics 12 (6), 595, 2020
112020
Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression
A Aiderus, JY Newberg, L Guzman-Rojas, AM Contreras-Sandoval, ...
PLoS genetics 17 (8), e1009094, 2021
62021
Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation
A Aiderus, AM Contreras-Sandoval, AL Meshey, JY Newberg, JM Ward, ...
Cancers 13 (2), 225, 2021
22021
161 Harnessing Sleeping Beauty transposon mutagenesis to model tumor heterogeneity in melanoma preclinical models
AM Contreras-Sandoval, MB Mann
Journal of Investigative Dermatology 139 (5), S28, 2019
2019
Development of an in-vivo platform to evaluate the PK-PD relationship of an anti-PD-L1 mAb in a syngeneic mouse model of melanoma
AM Contreras
2017
Understanding the effect mechanism through the good biomarker: Anti-PD-L1 immunotherapy
A Contreras, M Merino, P Berraondo, M Garrido
EUROPEAN JOURNAL OF CANCER 55, S13-S14, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–10